Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of patients with relapsed refractory chronic lymphocytic leukemia (RR-CLL). We describe the characteristics, causes of discontinuation, and outcomes in patients who discontinued treatment with ibrutinib. One hundred twenty-se...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Jain, Preetesh, Keating, Michael, Wierda, William, Estrov, Zeev, Ferrajoli, Alessandra, Jain, Nitin, George, Binsah, James, Danelle, Kantarjian, Hagop, Burger, Jan, O’Brien, Susan
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2015
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4467871/
https://ncbi.nlm.nih.gov/pubmed/25573991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-09-603670
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados